Perampanel Suspension
Product Images NDC 72205-071

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Perampanel (NDC 72205-071). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Peram-oral-sus-carton-label (Peram Oral Sus Carton Label)

Peram-oral-sus-carton-label (Peram Oral Sus Carton Label)
This is information about Perampanel Oral Suspension, a medication supplied in a liquid form with a 20mL syringe for oral administration. The package includes a Medication Guide for patients. It is important to shake the bottle before each use and follow the specific administration instructions provided. The product should be discarded 90 days after opening and stored below 30°C (86°F) without freezing. Detailed dosage and usage instructions are available in the prescribing information. The medication is manufactured by MSN Pharmaceuticals Inc. and distributed by Novadoz Pharmaceuticals LLC.*
FDA Label Image

Peram-oral-sus-cntr-label (Peram Oral Sus Cntr Label)

Peram-oral-sus-cntr-label (Peram Oral Sus Cntr Label)
This text provides information about a medication called Perampanel in oral suspension form, including dosage instructions, storage guidance, contact information for Novadoz Pharmaceuticals LLC, and the recommendation to shake the bottle before each use. The medication guide should be dispensed to each patient. The medication should be discarded 90 days after first opening and should not be stored above 30°C (86°F) or frozen. Additionally, the packaging includes an NDC number and the date of issuance. For more details, visit www.NovadozPharma.com/Products.*
FDA Label Image

Peram-oral-sus-fig-01 (Peram Oral Sus Fig 01)

Peram-oral-sus-fig-01 (Peram Oral Sus Fig 01)
This text provides statistical data from three different studies comparing the effect of Perampanel versus Placebo on seizure frequency. The studies involved different dosages and sample sizes, with the analysis being based on ANCOVA including treatment and pooled country as factors. The results show a statistically significant difference favoring Perampanel over Placebo in reducing the baseline seizure frequency per 28 days.*
FDA Label Image

Peram-oral-sus-fig-02 (Peram Oral Sus Fig 02)

Peram-oral-sus-fig-02 (Peram Oral Sus Fig 02)
This text appears to be a table showing the proportion of patients at different levels of response or outcomes for different doses of Perampanel and a placebo. The table includes four columns for placebo, Perampanel 4 mg/day, Perampanel 8 mg/day, and Perampanel 12 mg/day. The categories seem to be related to the level of response, starting from "Worse" and proceeding with increasing percentages up to 100.*
FDA Label Image

Peram-oral-sus-fig-03 (Peram Oral Sus Fig 03)

Peram-oral-sus-fig-03 (Peram Oral Sus Fig 03)
This text shows data related to the proportion of patients in a study categorized by different treatment groups (Placebo and Ferampanel) based on the severity of their condition. The data appears to be split into different ranges such as 0 to <25%, 25 to <50%, 50 to <75%, and 75 to 100%. It seems to be part of a report or analysis regarding the effectiveness of these treatments on patients.*
FDA Label Image

Peram-oral-sus-fig-a (Peram Oral Sus Fig A)

Peram-oral-sus-fig-a (Peram Oral Sus Fig A)
FDA Label Image

Peram-oral-sus-fig-b (Peram Oral Sus Fig B)

Peram-oral-sus-fig-b (Peram Oral Sus Fig B)
FDA Label Image

Peram-oral-sus-fig-c (Peram Oral Sus Fig C)

Peram-oral-sus-fig-c (Peram Oral Sus Fig C)
FDA Label Image

Peram-oral-sus-fig-d (Peram Oral Sus Fig D)

Peram-oral-sus-fig-d (Peram Oral Sus Fig D)
FDA Label Image

Peram-oral-sus-fig-e (Peram Oral Sus Fig E)

Peram-oral-sus-fig-e (Peram Oral Sus Fig E)
FDA Label Image

Peram-oral-sus-fig-f (Peram Oral Sus Fig F)

Peram-oral-sus-fig-f (Peram Oral Sus Fig F)
FDA Label Image

Peram-oral-sus-fig-g (Peram Oral Sus Fig G)

Peram-oral-sus-fig-g (Peram Oral Sus Fig G)
FDA Label Image

Peram-oral-sus-fig-h (Peram Oral Sus Fig H)

Peram-oral-sus-fig-h (Peram Oral Sus Fig H)
FDA Label Image

Peram-oral-sus-fig-i (Peram Oral Sus Fig I)

Peram-oral-sus-fig-i (Peram Oral Sus Fig I)
FDA Label Image

Peram-oral-sus-fig-j (Peram Oral Sus Fig J)

Peram-oral-sus-fig-j (Peram Oral Sus Fig J)
FDA Label Image

Peram-oral-sus-fig-k (Peram Oral Sus Fig K)

Peram-oral-sus-fig-k (Peram Oral Sus Fig K)
FDA Label Image

Peram-oral-sus-structure (Peram Oral Sus Structure)

Peram-oral-sus-structure (Peram Oral Sus Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.